Last reviewed · How we verify
Plasmodium immunotherapy
At a glance
| Generic name | Plasmodium immunotherapy |
|---|---|
| Sponsor | CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Plasmodium Immunotherapy for Advanced Ovarian Cancer (PHASE2, PHASE3)
- Plasmodium Immunotherapy for Advanced Cancers (PHASE1, PHASE2)
- Plasmodium Immunotherapy for Advanced Malignant Solid Tumors (PHASE1, PHASE2)
- Plasmodium Immunotherapy for Breast and Liver Cancers (PHASE1, PHASE2)
- Plasmodium Immunotherapy for Lung Cancer (PHASE1, PHASE2)
- Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis (PHASE1, PHASE2)
- Experimental Human Malaria Infection After Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis (NA)
- Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Versus Mefloquine Prophylaxis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |